We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
GlaxoSmithKline (GSK) yesterday unveiled plans for what it calls the “New GSK,” including focused investment in the development of vaccines and specialty medicines, which it predicts will make up the largest share of the company’s revenue within five years. Read More
Lehi, Utah-based Civica Rx is a collaborator in a U.S. government-funded partnership with Phlow, which secured a $354 million government contract in May 2020. Read More
Civica Rx, a two-year-old nonprofit organization launched to address generic drug shortages in the U.S., announced that drugmaker Catalent and health insurance giant Anthem are joining the organization’s new CivicaScript operating unit that focuses on making generic drugs. Read More
GSK is expanding its reach in cancer immunotherapies in a $2.1 billion deal with iTeos Therapeutics to co-develop EOS-448, a monoclonal antibody aimed at getting the body’s immune system to recognize and attack cancer cells. Read More
The U.S. government will pay Merck an estimated $1.2 billion for 1.7 million courses of its experimental COVID-19 antiviral, molnupiravir, if the drug is authorized by the FDA. Read More